Baidu
map

Oncogene:胰腺癌转移机制解析

2013-04-10 佚名 生物通

    胰腺癌是恶性度高、预后差的一种肿瘤,患者的5年生存率一般不到5%。由于胰腺的位置隐蔽,早期胰腺癌很难被发现,多数患者确诊时已是晚期,加之病死率极高,因此被称为“癌中之王”。  近日来自北卡罗来纳大学教堂山分校的研究人员证实,存在于胰腺癌周围细胞中的一种蛋白,在癌症扩散中发挥了重要作用。这一研究发现发表在3月25日的《Oncogene》杂志上。  在这篇文章中,

    胰腺癌是恶性度高、预后差的一种肿瘤,患者的5年生存率一般不到5%。由于胰腺的位置隐蔽,早期胰腺癌很难被发现,多数患者确诊时已是晚期,加之病死率极高,因此被称为“癌中之王”。
  近日来自北卡罗来纳大学教堂山分校的研究人员证实,存在于胰腺癌周围细胞中的一种蛋白,在癌症扩散中发挥了重要作用。这一研究发现发表在3月25日的《Oncogene》杂志上。
  在这篇文章中,北卡罗来纳大学教堂山分校细胞生物学和生理学教授Carol Otey领导研究小组发现,一种称作palladin的蛋白质促进了癌相关成纤维细胞(cancer-associated fibroblasts,CAFs)装配侵入性伪足(invadopodia),打破细胞间的壁垒,为肿瘤扩散至全身建立通道。
  “越来越多的研究表明,这些细胞在癌症形成和转移中发挥作用,”Otey说。
  利用酶促作用和物理力,侵入性伪足为肿瘤细胞从原始病灶迁移至其他器官建立了通道。Otey说,研究人员利用悬浮在胶原层之间的培养癌细胞,能够观察到CAFs通过了胶原层,并记录了癌细胞迁移通过这些通道的过程。
  在以往的研究中,Otey和其他实验室的研究人员已证实,胰腺癌周围的CAFs可以表达高水平的palladin。在健康组织中,成纤维细胞是哺乳动物最常见结缔组织类型的主要细胞成分。在肿瘤细胞中,CAFs是肿瘤微环境中数量最多的细胞类型。
  研究人员一开始就将焦点放在肿瘤微环境上,近年来越来越多的证据表明非癌性细胞和癌细胞外蛋白在肿瘤形成、生长和转移中发挥了至关重要的作用。了解微环境与肿瘤之间的相互作用,有可能促使发现新的癌症治疗和筛查靶点,尤其是对于那些对直接靶向性治疗耐受的癌症。
  “这些细胞似乎伙同在一起,形成肿瘤并促进了其生长,”Otey说。
  利用药物抑制剂和基因沉默方法,Otey和研究小组发现破坏CAFs中的palladin,可以抑制细胞形成侵入性伪足的能力。与之相反,在CAFs中提高palladin的水平,可以提高小鼠模型中肿瘤的生长和转移速率。这些结果表明,palladin有可能是涉及蛋白激酶C和Cdc42的一个分子信号通路的组成部分。
  “这些结果证实,CAFs行为在调节肿瘤细胞行为中起重要作用,也指出了一条特异的分子信号通路,其有可能成为抑制肿瘤进程的一个有用的药物靶点,”Otey说。自Otey10多年前发现palladin以来,她的实验室抑制在调查这一蛋白在健康和癌细胞中的作用。在以往的研究中,她和其他研究室也曾证实高水平的palladin与肾癌患者的低生存率密切相关。Otey说,研究数据指出CAFs中的palladin表达和肿瘤进程的侵袭性之间存在强相关性。
  在未来的研究中,Otey计划进一步检测其他癌症类型中的palladin水平。

胰腺癌相关的拓展阅读:


Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts.
Abstract
The stromal compartment surrounding epithelial-derived pancreatic tumors is thought to have a key role in the aggressive phenotype of this malignancy. Emerging evidence suggests that cancer-associated fibroblasts (CAFs), the most abundant cells in the stroma of pancreatic tumors, contribute to the tumor's invasion, metastasis and resistance to therapy, but the precise molecular mechanisms that regulate CAFs behavior are poorly understood. In this study, we utilized immortalized human pancreatic CAFs to investigate molecular pathways that control the matrix-remodeling and invasion-promoting activity of CAFs. We showed previously that palladin, an actin-associated protein, is expressed at high levels in CAFs of pancreatic tumors and other solid tumors, and also in an immortalized line of human CAFs. In this study, we found that short-term exposure of CAFs to phorbol esters reduced the number of stress fibers and triggered the appearance of individual invadopodia and invadopodial rosettes in CAFs. Molecular analysis of invadopodia revealed that their composition resembled that of similar structures (that is, invadopodia and podosomes) described in other cell types. Pharmacological inhibition and small interfering RNA knockdown experiments demonstrated that protein kinase C, the small GTPase Cdc42 and palladin were necessary for the efficient assembly of invadopodia by CAFs. In addition, GTPase activity assays showed that palladin contributes to the activation of Cdc42. In mouse xenograft experiments using a mixture of CAFs and tumor cells, palladin expression in CAFs promoted the rapid growth and metastasis of human pancreatic tumor cells. Overall, these results indicate that high levels of palladin expression in CAFs enhance their ability to remodel the extracellular matrix by regulating the activity of Cdc42, which in turn promotes the assembly of matrix-degrading invadopodia in CAFs and tumor cell invasion. Together, these results identify a novel molecular signaling pathway that may provide new molecular targets for the inhibition of pancreatic cancer metastasis.Oncogene advance online publication, 25 March 2013; doi:10.1038/onc.2013.68.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672683, encodeId=896a16e2683e5, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Oct 22 13:32:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048503, encodeId=53d92048503ae, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Aug 11 08:32:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558011, encodeId=6053155801170, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590239, encodeId=0ab515902391f, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
    2013-10-22 hongbochen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672683, encodeId=896a16e2683e5, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Oct 22 13:32:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048503, encodeId=53d92048503ae, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Aug 11 08:32:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558011, encodeId=6053155801170, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590239, encodeId=0ab515902391f, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
    2013-08-11 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672683, encodeId=896a16e2683e5, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Oct 22 13:32:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048503, encodeId=53d92048503ae, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Aug 11 08:32:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558011, encodeId=6053155801170, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590239, encodeId=0ab515902391f, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
    2013-04-12 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672683, encodeId=896a16e2683e5, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Oct 22 13:32:00 CST 2013, time=2013-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048503, encodeId=53d92048503ae, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Aug 11 08:32:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558011, encodeId=6053155801170, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590239, encodeId=0ab515902391f, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Apr 12 01:32:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]

相关资讯

美研究发现苦瓜可抑制胰腺癌

俄罗斯《论据与事实》周报网站3月20日报道,中国产的苦瓜可抑制癌细胞获取葡萄糖的能力,使其失去能量支持而死去。 美国科学家在对实验鼠进行研究后得出了上述结论。研究人员给实验鼠喂苦瓜汁,结果它们体内胰腺恶性肿瘤发展的几率降低了60%。 此前的研究显示,苦瓜果实可帮助治愈Ⅱ型糖尿病。这一蔬菜中的生物活性化合物能激活机体里一种叫AM PK的酶,这种酶有助于肌肉和脂肪细胞更有效地利用葡萄糖。

卡培他滨化放疗用于局部胰腺癌疗效佳

  旧金山——一项纳入74例局部晚期胰腺癌患者的随机试验显示,在诱导化疗之后给予放疗加卡培他滨,似乎与诱导化疗序贯放疗加吉西他滨具有同等疗效,而毒性更低。   英国牛津大学的Somnath Mukherjee博士在美国临床肿瘤学会胃肠肿瘤(ASCO GI)研讨会上指出,关于局部晚期胰腺癌的最佳治疗目前尚未形成共识。既往试验结果提示,单纯化疗或化放疗的中位生存期约为10个月。一项Meta分析显示,

触发胰腺癌需要一个以上的致癌基因

    来自梅奥诊所的研究人员在新研究中证实触发胰腺癌需要一个以上的致癌基因,第二个因子创造了“完美风暴”使得肿瘤得以形成。这一发表在9月10日《癌细胞》(Cancer Cell)杂志上的论文颠覆了当前所认为的KRAS癌基因突变就足以触发胰腺癌和无限制的细胞生长的观点。     研究结果揭示了关于胰腺癌形成机制和只有少数患者受益于当前治

AJG:大量吸烟酗酒与较早患胰腺癌有关

    美国密歇根大学研究人员日前发表的报告显示,大量吸烟、酗酒与较早患胰腺癌风险之间有关联。   研究人员对“胰腺癌协作登记”国际数据库中811名胰腺癌患者的信息进行研究后发现,其中大量吸烟者被诊断患胰腺癌时的平均年龄约为62岁,酗酒者被发现患胰腺癌时的平均年龄约为61岁,而不吸烟、酗酒的胰腺癌患者患该病的平均年龄约为72岁。不过,大量吸烟和酗酒的有害影响可以逆转

STM:中药成分雷公藤甲素可抗胰腺癌

  美国明尼苏达大学研究人员日前报告说,小鼠模型显示在传统中药中有悠久使用历史的天然植物产品——雷公藤甲素对治疗胰腺癌有效。   此前有研究表明,胰腺癌细胞可能含有过多HSP70蛋白,后者能保护癌细胞免于死亡。明尼苏达大学研究人员发现,雷公藤甲素可降低胰腺癌细胞中的HSP70浓度,进而减少小鼠体内的肿瘤细胞。   不过,由于雷公藤甲素不溶于水,它在小鼠体内的作用不甚理想。研究人员于是对雷公藤甲

CA-CANCER J CLIN :血栓栓塞预示胰腺癌不良预后

Illustration 1. The study showed a 36% incidence of thromboembolism in patients with exocrine pancreatic cancer.     近来的研究证实血栓栓塞(TE)是外分泌胰腺癌患者的显著风险因子,其发生率约为36%且预示着不良预后(Cancer [published online

Baidu
map
Baidu
map
Baidu
map